JETPHARMA
ActiveJETPHARMA has been active since 2012 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €14k and a net result of €22k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 29% of 17987 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.3% (low).
Checked score
Score 2025
Axes · tick = 2024
Profitability100▲+100
Solvency19▼-23
Growth58=
Stability100
Bankruptcy probability, 12 months
1.3%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €1k at 30 days acceptable
Liquidity tight (current ratio 1.05 against 0.89 in 2024), and 90.2% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
9.8%
Return on assets
15.1%
Age of the figures
8 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 15-07-2026, 16 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
16 d early
2024
29 d early
2023
26 d early
2022
12 d early
2021
20 d early
2020
23 d early
2019
25 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
13-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€14k
2024 · €-8k
2018: €35k
2019: €28k
2020: €21k
2021: €-7k
2022: €-40k
2023: €-42k
2024: €-8k
2018 → 2025
Total assets
€146k▲ 9.0%
2024 · €134k
2018: €260k
2019: €223k
2020: €206k
2021: €160k
2022: €113k
2023: €113k
2024: €134k
2018 → 2025
Net result
€22k▼ 34.8%
2024 · €34k
2018: €-8k
2019: €-6k
2020: €-7k
2021: €-28k
2022: €-33k
2023: €-2k
2024: €34k
2018 → 2025
Working capital
€7k
2024 · €-16k
2018: €-95k
2019: €-72k
2020: €-46k
2021: €-44k
2022: €-41k
2023: €-42k
2024: €-16k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€-7k-€-40k▼ 485%€-42k▼ 5.3%€-8k▲ 81.2%€14k
Operating result€-25k-€-27k▼ 4.5%€5k€42k▲ 736%€27k▼ 35.6%
Net result€-28k-€-33k▼ 17.7%€-2k▲ 93.6%€34k€22k▼ 34.8%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 36% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €146k
Fixed assets
€7k▼ 28.1%
Current assets
€139k▲ 12.1%
Equity and liabilities €146k
Equity
€14k
Debt
€132k
Debt finances 90.2% of the balance-sheet total.
Key figures and ratios
EBITDA
€30k▼
2024 · €43k
Cash flow
€25k▼
2024 · €35k
Solvency
9.8%▲
2024 · -5.9%
Current ratio
1.05▲
2024 · 0.89
Quick ratio
0.41▲
2024 · 0.31
Debt / equity
9.25▲
2024 · -18.01
ROE
155.3%▲
2024 · -430.6%
ROA
15.1%▼
2024 · 25.3%
Interest coverage
5.96▲
2024 · 5.17
Debt
€132k▼
2024 · €142k
Debt ≤ 1 year
€132k▼
2024 · €140k
Income taxes
€64▲
2024 · €59
Staff costs
€87k▲
2024 · €76k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€134k€146k▲
Fixed assets21/28€10k€7k▼
Tangible fixed assets22/27€8k€5k▼
Plant, machinery and equipment23€8k€5k▼
Financial fixed assets28€2k€2k=
Current assets29/58€124k€139k▲
Stocks and contracts in progress3€80k€85k▲
Stocks30/36€80k€85k▲
Amounts receivable within one year40/41€40k€48k▲
Trade receivables40€40k€48k▲
Cash at bank and in hand54/58€4k€5k▲
Deferred charges and accrued income490/1€408€2k▲
Equity and liabilities
Total equity and liabilities10/49€134k€146k▲
Equity10/15€-8k€14k▲
Contributions10/11€100k€100k=
Reserves13€10€10=
Distributable reserves133€10€10=
Profit (loss) carried forward14€-108k€-86k▲
Amounts payable17/49€142k€132k▼
Amounts payable within one year42/48€140k€132k▼
Financial debts43€3k€3k▼
Credit institutions430/8€3k€3k▼
Trade debts44€53k€67k▲
Suppliers440/4€53k€67k▲
Taxes, remuneration and social security45€19k€20k▲
Taxes450/3€3k€4k▲
Remuneration and social security454/9€16k€17k▲
Other amounts payable47/48€64k€41k▼
Accrued charges and deferred income492/3€3k€248▼
Income statement
Code20242025
Non-recurring operating income76A-€3k
Remuneration, social security and pensions62€76k€87k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€910€3k▲
Other operating charges640/8€193€61▼
Gross operating margin9900€119k€118k▼
Operating profit (loss)9901€42k€27k▼
Financial income75/76B€18€3▼
Recurring financial income75€18€3▼
Financial charges65/66B€8k€5k▼
Recurring financial charges65€8k€5k▼
Profit (loss) for the period before taxes9903€34k€22k▼
Income taxes67/77€59€64▲
Profit (loss) for the period9904€34k€22k▼
Profit (loss) for the period to be appropriated9905€34k€22k▼
Appropriation of the result
Profit (loss) to be appropriated9906€-108k€-86k▲
Profit (loss) brought forward from the previous period14P€-142k€-108k▲
The notes to these accounts (7 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
15-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
02-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
31-12
Financial
Back to profitnet €34k
Net result €34k after 6 loss-making years.
05-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
19-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
31-12
Financial
Weakest financial yearnet €-33k
Net result drops to €-33k, the lowest in the series; recovery starts the following year.
11-07
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
08-07
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
06-07
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
01-08
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema · 1 day late
2018
27-08
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema · 27 days late
2017
06-09
NBB filing
Annual accounts filed
fiscal year 2016 · full schema · 37 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
3 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Jette · 1 establishment unit since 2013
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Grondwetlaan 1021090 JetteGround area
714 m²
Building footprint
359 m²
Volume, LiDAR
5,047 m³
2 parcels, Brussels · tallest building 19.3 m, ±5 floors. Linked by address, not a title deed.
1 establishment unit
Jetse Steenweg 321, 1090 Jette
since 20132.217.017.845
2 parcels
Brussels
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21464E0038/00B013 | Brussels | 583 m² | 1 · 227 m² | 19.3 m · 5 fl. |
| 21464D0039/00L002 | Brussels | 132 m² | 1 · 132 m² | 14.1 m · 4 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
Apotheker Van De Weghe Karen
BE 0662.425.965
Deinze · Eq €14k
PHARMA WILSON
BE 1016.645.518
Montigny-le-Tilleul · Eq €14k
T.R.F. pharma
BE 1017.867.223
Fléron · Eq €14k
Sagenex
BE 0460.691.897
Namur · Eq €14k
CAMILLE HUBY
BE 0800.339.476
Etterbeek · Eq €14k
Of 5,208 companies in sector 47730 we hold annual accounts for 3,850. 1,107 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded27-12-2012
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 13 filingsAddress and cadastre registers
Data from official sources, last processed on 12-09-2026. Scores and ratios are computed by Checked and are not a credit decision.